Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06684522 · ClinicalTrials.gov registry record · Early Phase 1
Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
A Early Phase 1 study, sponsored by Northwestern University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT06684522: Recruiting Early Phase 1 study, sponsored by Northwestern University.
NCT06684522 is a Early Phase 1 study that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 10 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06684522, a Early Phase 1 study, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Primary Outcome
Reduction in baseline IGA score at week 12 compared to week 0
Interventions
- DRUG Upadacitinib 15 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2027-06 |
| Phase | Early Phase 1 |
What NCT06684522 shows while recruiting
NCT06684522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Upadacitinib 15 MG is the first listed.
NCT06684522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06684522 about?
NCT06684522 is a clinical study titled "Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis". This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
What is the current status of trial NCT06684522?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2025-12-18. Estimated completion is 2027-06.
What interventions are being tested in trial NCT06684522?
The interventions under investigation include: Upadacitinib 15 MG (DRUG).
Who is sponsoring clinical trial NCT06684522?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06684522's enrollment target sits among peer trials
10 1629th of 2000 higher than 256 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI